Home › Quarterly results › Pharmaceuticals
Pharmaceuticals: Q1 FY27 results (April-June 2026)
106 companies have declared Pharmaceuticals Q1 FY27 results so far, the latest on 21 Sep 2026.
Across the 99 non-financial companies with a year-ago quarter to compare, sales grew +13.6% and net profit +7.6% year on year, and the combined operating margin narrowed 144 bps to 21.6%.
68% of companies grew net profit; 5 turned a loss into a profit; 47% beat their own profit trend and 40% fell short of it.
Latest results
Results calendar
Q2 FY27 Q1 FY27 Q4 FY26 Q3 FY26 Q2 FY26
Pharmaceuticals Q1 FY27 scoreboard
Sales growth
+13.6%
YoY, 99 companies combined; median +17.0%
Net profit growth
+7.6%
YoY combined; median +26.1%
Operating margin
21.6%
-144 bps YoY
Grew profit
68%
5 turnarounds, 4 into loss
Vs own profit trend
47% / 40%
above / below, 13% in line
Price since results
-2.1%
median; 46% of 98 stocks up
Other-income heavy
24
25%+ of pre-tax profit from other income & one-offs
Latest Pharmaceuticals Q1 FY27 results 106
Page 1 of 4
Tap ☆ on any company to add it to My companies. Your list stays in this browser.
M Cap ₹6,826 Cr
P/E —
PEG —
Since results -3.7%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
218 — — Operating profit
— —
45.2 — — OPM %
— —
20.7% — — Other income
— —
0.3 — — Net profit
— —
14.1 — — PAT margin %
— —
6.4% — — EPS (₹)
— —
2.24 — —
Quality of profit
Pre-tax profit ₹17.5 Cr: core business ₹17.2 Cr, other income ₹0.3 Cr.
Core profit YoY: —
AI read of the filing Symbiotec Pharmalab Posts Q1 FY27 Results; Reports Standalone Loss of ₹156.90M Amid Recent Listing Negative Standalone net loss stood at ₹156.90 million for Q1 FY27 compared to a net profit of ₹445.05 million in Q1 FY26 Basic and diluted EPS dropped to negative ₹2.73 and ₹2.71 respectively for the quarter ended June 30, 2026 Completed IPO of 17,786,442 equity shares at ₹988 per share, consisting of a ₹1,500.00 million fresh issue and ₹16,070.00 million OFS Full analysis →
M Cap ₹347 Cr
P/E 83.2
PEG 41.59
Since results +20.8%
Profit -21% below its own trend Operating margin expanded 130 bps YoY All of pre-tax profit came from other income or one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
-56.3% -76.4%
44.6 189 102 Operating profit
-22.5% -69.5%
1.3 4.3 1.7 OPM %
+130 bps +68 bps
3.0% 2.3% 1.7% Other income
+10.6% from loss 1.7 -0.4 1.6 Net profit
-25.3% -34.4%
1.0 1.6 1.4 PAT margin %
+95 bps +147 bps
2.3% 0.8% 1.3% EPS (₹)
-25.0% -34.5%
0.36 0.55 0.48
Quality of profit
Pre-tax profit ₹0.5 Cr: core business −₹1.2 Cr, other income ₹1.7 Cr.
Core profit YoY: to loss
· reported profit -25.3%
Cash & debt
FY26 cash from operations ₹10.0 Cr:
221% of FY26 net profit of ₹4.5 Cr.
Borrowings ₹50.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹82.1 ₹44.6
-45.6% below Net profit ₹1.3 ₹1.0
-21.3% below
AI read of the filing Q1 Revenue Falls 56.3% YoY to Rs 44.63 Cr; Net Profit Declines 25.3% to Rs 1.02 Cr Negative Revenue from operations plunged 56.3% YoY to Rs 4,462.55 lakhs from Rs 10,220.83 lakhs in Q1 FY26 Profit before tax contracted 70.2% YoY to Rs 51.56 lakhs compared to Rs 172.82 lakhs in Q1 FY26 Net profit came in at Rs 102.37 lakhs versus Rs 137.13 lakhs in Q1 FY26, down 25.3% YoY Full analysis →
M Cap ₹2,347 Cr
P/E 145.6
PEG 1.04
Since results -22.1%
Into loss: a profit a year ago Profit -303% below its own trend Operating margin contracted 1105 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
-4.3% -20.4%
678 851 708 Operating profit
-57.4% -63.1%
60.1 163 141 OPM %
-1105 bps -1029 bps
8.9% 19.2% 19.9% Other income
-17.5% +21.1%
18.2 15.0 22.0 Net profit
to loss to loss -57.9 22.0 23.0 PAT margin %
-1179 bps -1113 bps
-8.5% 2.6% 3.2%
Quality of profit
Pre-tax profit −₹51.2 Cr: core business −₹67.7 Cr, other income ₹18.2 Cr, exceptional & other items −₹1.7 Cr.
Core profit YoY: to loss
Cash & debt
FY26 cash from operations ₹491 Cr:
506% of FY26 net profit of ₹97.0 Cr.
Borrowings ₹3,076 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹794 ₹678
-14.7% below Net profit ₹28.5 −₹57.9
-302.9% below
AI read of the filing DCAL Posts Q1 Net Loss of ₹57.88 Cr vs Profit of ₹23.41 Cr YoY; Revenue Drops to ₹677.64 Cr Negative Consolidated revenue from operations declined 4.29% YoY to ₹677.64 Cr (vs ₹708.05 Cr in Q1 FY26 and ₹851.40 Cr in Q4 FY26) Swung to a net loss of ₹57.88 Cr from a net profit of ₹23.41 Cr in Q1 FY26 Operating EBITDA margin shrank to 8.87% vs 19.87% in Q1 FY26 and 19.14% in Q4 FY26 Full analysis →
M Cap ₹11.0 Cr
P/E —
PEG —
Since results -10.3%
Operating margin contracted 188937 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
-80.0% -94.7%
0.0 0.3 0.1 Operating profit
loss widened loss widened -0.3 -0.0 -0.2 OPM %
-188937 bps -208604 bps
-2089.4% -3.3% -200.0% Other income
— —
0.0 0.0 0.0 Net profit
loss widened loss widened -0.3 -0.0 -0.2 PAT margin %
-188688 bps -210854 bps
-2111.9% -3.3% -225.0% EPS (₹)
loss widened loss widened -0.42 -0.01 -0.22
Quality of profit
Pre-tax profit −₹0.3 Cr: core business −₹0.3 Cr, other income ₹0.0 Cr.
Core profit YoY: loss widened
Cash & debt
FY26 cash from operations −₹0.6 Cr.
Borrowings ₹1.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹0.0 ₹0.0
-60.0% below
AI read of the filing Q1 FY27 Net Loss Widens to ₹33.79 Lakh as Total Income Drops 80% YoY to ₹1.60 Lakh Negative Total Income dropped 80.2% YoY to ₹1.60 lakh compared to ₹8.09 lakh in Q1 FY26 Net loss widened to ₹33.79 lakh versus ₹17.54 lakh in Q1 FY26 and ₹0.93 lakh in Q4 FY26 Net sales from operations remained minimal at ₹1.16 lakh vs ₹3.98 lakh in Q1 FY26 Full analysis →
M Cap ₹4,074 Cr
P/E 55.4
PEG —
Since results -1.8%
Profit +141% above its own trend Operating margin expanded 298 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+16.6% +3.5%
261 252 224 Operating profit
+40.0% -0.8%
46.6 47.0 33.3 OPM %
+298 bps -78 bps
17.9% 18.7% 14.9% Other income
-50.6% from loss 0.5 -1.0 0.9 Net profit
+70.7% +1.4%
22.3 22.0 13.1 PAT margin %
+271 bps -18 bps
8.6% 8.7% 5.8% EPS (₹)
+70.8% +1.8%
2.22 2.18 1.30
Quality of profit
Pre-tax profit ₹30.0 Cr: core business ₹29.6 Cr, other income ₹0.5 Cr.
Core profit YoY: +80.9%
· reported profit +70.7%
Cash & debt
FY26 cash from operations ₹45.0 Cr:
70% of FY26 net profit of ₹64.3 Cr.
Borrowings ₹405 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹254 ₹261
+2.5% in line Net profit ₹9.3 ₹22.3
+141.1% above
AI read of the filing Q1 FY27 Consolidated PAT jumps 70.7% YoY to ₹22.31 Cr; approves Philippines arm Positive Consolidated Net Profit jumped 70.7% YoY to ₹22.31 Cr (₹2,231.28 Lakhs) in Q1 FY27 vs ₹13.07 Cr in Q1 FY26. Consolidated Revenue from Operations grew 16.58% YoY to ₹260.82 Cr vs ₹223.72 Cr in the prior-year period. Basic EPS increased to ₹2.22 for Q1 FY27 from ₹1.30 reported in Q1 FY26. Full analysis →
M Cap ₹27.0 Cr
P/E —
PEG —
Since results -24.7%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
1.2 — — Operating profit
— —
-1.4 — — OPM %
— —
-113.4% — — Other income
— —
0.1 — — Net profit
— —
-3.6 — — PAT margin %
— —
-291.7% — — EPS (₹)
— —
-0.71 — —
Quality of profit
Pre-tax profit −₹3.5 Cr: core business −₹3.1 Cr, other income ₹0.1 Cr.
Core profit YoY: —
AI read of the filing Lasa Supergenerics Q1 FY27: Auditor Flags Going Concern, Stalled Ops & ₹38.1 Cr GST Demands Negative Manufacturing operations remain completely halted across all units following the uninsured fire incident on May 18, 2025 (₹20.57 Cr loss recognized earlier). Auditor flagged going concern uncertainties; asset impairment remains unquantified as labor strikes obstruct physical site inspection. Contingent GST demand notices total ₹3,810.93 Lakhs (₹38.11 Cr), representing ~152% of TTM revenue and exceeding market cap (₹37 Cr). Full analysis →
M Cap ₹25,565 Cr
P/E —
PEG —
Since results -5.1%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
— —
534 — — Operating profit
— —
129 — — OPM %
— —
24.2% — — Other income
— —
5.7 — — Net profit
— —
84.8 — — PAT margin %
— —
15.9% — — EPS (₹)
— —
5.13 — —
Quality of profit
Pre-tax profit ₹110 Cr: core business ₹105 Cr, other income ₹5.7 Cr.
Core profit YoY: —
AI read of the filing 95.8% YoY PAT Growth; Rubicon Reports ₹84.8 Cr Profit in Q1 FY27 with New Acquisitions Positive Consolidated revenue from operations grew 51.6% YoY to ₹534.34 cr. Net profit (PAT) increased 95.8% YoY to ₹84.78 cr from ₹43.30 cr in the year-ago period. Completed the acquisition of an 85% stake in Arinna Lifesciences for ₹175.92 cr on April 30, 2026. Full analysis →
M Cap ₹408 Cr
P/E 1.1
PEG —
Since results +26.3%
Profit -42% below its own trend Operating margin contracted 169 bps YoY 34% of pre-tax profit came from other income and one-off items Operating cash flow was negative in FY26 despite a profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+11.3% -21.0%
47.9 60.6 43.0 Operating profit
-6.3% -20.3%
4.3 5.4 4.6 OPM %
-169 bps +8 bps
9.0% 9.0% 10.7% Other income
+83.2% -50.5%
0.9 1.7 0.5 Net profit
+15.3% -58.5%
1.8 4.5 1.6 PAT margin %
+14 bps -348 bps
3.9% 7.3% 3.7%
Quality of profit
Pre-tax profit ₹2.6 Cr: core business ₹1.7 Cr, other income ₹0.9 Cr.
Core profit YoY: +3.0%
· reported profit +15.3%
Cash & debt
FY26 cash from operations −₹33.0 Cr:
-9% of FY26 net profit of ₹381 Cr.
Borrowings ₹48.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹86.1 ₹47.9
-44.4% below Net profit ₹3.2 ₹1.8
-42.3% below
AI read of the filing Medicamen Biotech Q1 Net Profit Up 15% YoY to ₹1.85 Cr; ₹1 Dividend Recommended Neutral Consolidated Total Revenue reached ₹48.76 Cr, up 12.1% from ₹43.52 Cr in Q1 FY26. Consolidated Net Profit stood at ₹1.85 Cr, a 15.3% increase compared to ₹1.60 Cr in the year-ago period. Proposed a final dividend of ₹1.00 per equity share (10%) for the financial year 2025-26. Full analysis →
M Cap ₹14,397 Cr
P/E 13.3
PEG 0.51
Since results -15.9%
Profit -40% below its own trend Operating margin contracted 1760 bps YoY 32% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
-44.7% -0.5%
735 739 1,329 Operating profit
-67.3% +45.7%
186 128 571 OPM %
-1760 bps +805 bps
25.4% 17.3% 43.0% Other income
-4.5% -24.1%
59.2 78.0 62.0 Net profit
-55.5% -23.2%
206 269 464 PAT margin %
-683 bps -831 bps
28.1% 36.4% 34.9% EPS (₹)
-57.0% -22.9%
11.53 14.96 26.84
Quality of profit
Pre-tax profit ₹186 Cr: core business ₹126 Cr, other income ₹59.2 Cr.
Core profit YoY: -75.2%
· reported profit -55.5%
Cash & debt
FY26 cash from operations ₹1,768 Cr:
132% of FY26 net profit of ₹1,341 Cr.
Borrowings ₹714 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹1,309 ₹735
-43.8% below Net profit ₹345 ₹206
-40.2% below
AI read of the filing Natco Pharma Q1 PAT drops 57% to ₹206.5 Cr; Board proposes ₹2000 Cr fundraise Negative Consolidated revenue declined 43% YoY to ₹794.4 Cr in Q1 FY27 from ₹1,390.6 Cr. Net profit for the quarter fell 57% YoY to ₹206.5 Cr compared to ₹480.3 Cr in the previous year. International formulations revenue saw a sharp drop of 57.4% YoY to ₹477.1 Cr. Full analysis →
M Cap ₹63,118 Cr
P/E 28.9
PEG 0.90
Since results -3.7%
Profit -27% below its own trend Operating margin contracted 144 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+10.9% +3.8%
3,740 3,603 3,371 Operating profit
+3.6% +48.2%
766 517 739 OPM %
-144 bps +613 bps
20.5% 14.3% 21.9% Other income
+2.5% +135.0%
153 65.0 149 Net profit
-21.6% +107.6%
521 251 664 PAT margin %
-578 bps +696 bps
13.9% 7.0% 19.7% EPS (₹)
-21.7% +119.9%
43.49 19.78 55.56
Quality of profit
Pre-tax profit ₹772 Cr: core business ₹619 Cr, other income ₹153 Cr.
Core profit YoY: -0.3%
· reported profit -21.6%
Cash & debt
FY26 cash from operations ₹1,963 Cr:
84% of FY26 net profit of ₹2,330 Cr.
Borrowings ₹2,047 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹3,806 ₹3,740
-1.7% in line Net profit ₹713 ₹521
-27.0% below
AI read of the filing Alkem Q1 FY27 Standalone EPS at ₹47.67; Generic Business Slump Sale Completed Neutral Standalone Basic EPS for Q1 FY27 stood at ₹47.67 vs ₹52.04 in Q1 FY26 (restated) Generic business (discontinued) contributed ₹918.1 Cr in total income during FY26 Exceptional impairment of ₹74.7 Cr recognized in FY26 regarding real estate investments Full analysis →
M Cap ₹120 Cr
P/E 27.4
PEG 4.57
Since results -13.9%
Profit -83% below its own trend Operating margin contracted 1875 bps YoY All of pre-tax profit came from other income or one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+25.2% -23.8%
23.9 31.4 19.1 Operating profit
to loss to loss -4.0 3.6 0.4 OPM %
-1875 bps -2800 bps
-16.5% 11.5% 2.2% Other income
-51.7% from loss 5.8 -0.2 11.9 Net profit
-91.7% -29.0%
1.0 1.4 11.8 PAT margin %
-5748 bps -30 bps
4.1% 4.4% 61.6% EPS (₹)
-91.2% -25.8%
0.49 0.66 5.59
Quality of profit
Pre-tax profit ₹1.0 Cr: core business −₹4.8 Cr, other income ₹5.8 Cr.
Core profit YoY: loss widened
· reported profit -91.7%
Cash & debt
FY26 cash from operations ₹10.0 Cr:
66% of FY26 net profit of ₹15.2 Cr.
Borrowings ₹3.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹18.6 ₹23.9
+28.8% above Net profit ₹5.9 ₹1.0
-83.3% below
AI read of the filing Rs 1.04 Cr Net Profit (Down 91% YoY) as Raw Material Costs Surge to 90% of Revenue Negative Revenue from operations increased 25.2% YoY to Rs 23.93 Cr from Rs 19.11 Cr. Standalone Net Profit fell 91.2% YoY to Rs 1.04 Cr, heavily reliant on non-operating income. Cost of materials consumed rose 80.3% YoY to Rs 21.53 Cr, representing 89.9% of revenue. Full analysis →
M Cap ₹845 Cr
P/E 28.9
PEG 0.64
Since results +28.0%
Profit -27% below its own trend Operating margin contracted 103 bps YoY 75% of pre-tax profit came from other income and one-off items Core business grew faster than reported profit (core profit +8%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+4.0% -49.9%
44.9 89.6 43.1 Operating profit
-10.1% -86.7%
2.9 22.1 3.3 OPM %
-103 bps -1817 bps
6.5% 24.7% 7.6% Other income
+13.3% +491.2%
2.9 0.5 2.6 Net profit
-13.0% -86.8%
2.0 14.9 2.3 PAT margin %
-86 bps -1222 bps
4.4% 16.6% 5.2% EPS (₹)
-55.9% -80.4%
0.83 4.24 1.88
Quality of profit
Pre-tax profit ₹3.9 Cr: core business ₹1.0 Cr, other income ₹2.9 Cr.
Core profit YoY: +8.3%
· reported profit -13.0%
Cash & debt
FY26 cash from operations ₹24.0 Cr:
81% of FY26 net profit of ₹29.5 Cr.
Borrowings ₹89.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹50.0 ₹44.9
-10.3% below Net profit ₹2.7 ₹2.0
-27.2% below
AI read of the filing 4% YoY Revenue Growth in Q1 FY27; Consolidated PAT Declines 13% to Rs 1.97 Cr Neutral Consolidated Revenue increased 4% YoY to Rs 44.88 Cr from Rs 43.14 Cr in the previous year's quarter. Consolidated PAT fell 13% YoY to Rs 1.97 Cr, down from Rs 2.26 Cr in Q1 FY26. Foreign subsidiary Kilitch Estro Biotech PLC reported a loss of Rs 2.87 Cr on revenue of Rs 3.97 Cr. Full analysis →
M Cap ₹207 Cr
P/E 15.6
PEG 0.33
Since results +3.1%
Into loss: a profit a year ago Operating margin contracted 414 bps YoY FY26 operating cash flow was only 37% of profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
-10.0% +13.6%
23.0 20.2 25.5 Operating profit
-40.4% +173.9%
1.9 0.7 3.1 OPM %
-414 bps +475 bps
8.1% 3.4% 12.3% Other income
-18.6% -86.9%
0.2 1.4 0.2 Net profit
to loss to loss -1.8 1.5 9.6 PAT margin %
-4535 bps -1530 bps
-7.8% 7.5% 37.6% EPS (₹)
to loss to loss -0.61 0.52 3.25
Quality of profit
Pre-tax profit −₹1.8 Cr: core business ₹1.2 Cr, other income ₹0.2 Cr, exceptional & other items −₹3.2 Cr.
Core profit YoY: -49.0%
Cash & debt
FY26 cash from operations ₹9.0 Cr:
37% of FY26 net profit of ₹24.6 Cr.
Borrowings ₹9.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹25.4 ₹23.0
-9.8% below
AI read of the filing Brooks Labs Q1 FY27: Consolidated Loss of ₹1.79 Cr vs ₹9.58 Cr Profit YoY Negative Consolidated revenue fell 10% YoY to ₹22.96 Cr from ₹25.51 Cr in the year-ago period Swung to a consolidated net loss of ₹1.79 Cr compared to a profit of ₹9.58 Cr in Q1 FY26 Share of loss from Joint Venture (Brooks Steriscience) stood at ₹3.21 Cr, impacting the bottom line Full analysis →
M Cap ₹6,822 Cr
P/E 34.4
PEG 1.04
Since results +6.9%
Profit -36% below its own trend Operating margin contracted 1063 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+30.8% -31.5%
190 277 145 Operating profit
-8.2% -51.6%
47.5 98.0 51.7 OPM %
-1063 bps -1037 bps
25.0% 35.4% 35.6% Other income
-1.0% -11.7%
2.6 3.0 2.7 Net profit
-30.9% -67.5%
24.0 74.0 34.8 PAT margin %
-1131 bps -1404 bps
12.7% 26.7% 24.0% EPS (₹)
-30.8% -67.6%
2.99 9.22 4.32
Quality of profit
Pre-tax profit ₹40.8 Cr: core business ₹38.1 Cr, other income ₹2.6 Cr.
Core profit YoY: -14.7%
· reported profit -30.9%
Cash & debt
Borrowings ₹5.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹168 ₹190
+13.0% above Net profit ₹37.5 ₹24.0
-35.9% below
AI read of the filing Supriya Lifescience Q1 PAT Drops 31% YoY to ₹24.04 Cr Despite 31% Revenue Growth Negative Revenue from operations grew 30.8% YoY to ₹189.75 cr, but fell 31.4% sequentially from ₹276.53 cr. Net Profit (PAT) contracted 30.9% YoY to ₹24.04 cr, down from ₹34.79 cr in Q1 FY26. Cost of materials consumed spiked to ₹109.40 cr, representing 57.6% of revenue compared to 30.2% in the year-ago quarter. Full analysis →
M Cap ₹2,115 Cr
P/E —
PEG —
Since results -16.1%
Operating margin expanded 355 bps YoY All of pre-tax profit came from other income or one-off items Exceptional items of ₹2.7 Cr in the quarter
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+19.7% +19.7%
200 167 167 Operating profit
from loss +120.6%
5.7 2.6 -1.2 OPM %
+355 bps +130 bps
2.8% 1.5% -0.7% Other income
-75.0% -19.4%
4.2 5.3 17.0 Net profit
-44.4% from loss 2.2 -1.0 4.0 PAT margin %
-127 bps +170 bps
1.1% -0.6% 2.4% EPS (₹)
-42.4% +375.0%
0.38 0.08 0.66
Quality of profit
Pre-tax profit ₹3.6 Cr: core business −₹3.4 Cr, other income ₹4.2 Cr, exceptional & other items ₹2.7 Cr.
Core profit YoY: loss narrowed
· reported profit -44.4%
Cash & debt
FY26 cash from operations ₹17.0 Cr.
Borrowings ₹24.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹189 ₹200
+5.5% above
AI read of the filing Panacea Biotec Q1 FY27: Revenue Grows 19.7% YoY to ₹199.57 Cr; Net Profit Declines to ₹2.20 Cr Neutral Consolidated revenue from operations rose to ₹199.57 Cr from ₹166.70 Cr in the year-ago period. Consolidated net profit after tax stood at ₹2.20 Cr, down from ₹3.96 Cr in Q1 FY26. Total consolidated expenses increased by 14.6% YoY to ₹202.98 Cr, driven by higher raw material costs. Full analysis →
M Cap ₹4,586 Cr
P/E —
PEG —
Since results +4.9%
Operating margin contracted 1053 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+66.9% +6.5%
174 163 104 Operating profit
to loss to loss -11.6 9.0 4.0 OPM %
-1053 bps -1220 bps
-6.7% 5.5% 3.8% Other income
+104.3% from loss 2.0 -3.0 1.0 Net profit
loss widened loss widened -43.9 -14.0 -14.0 PAT margin %
-1185 bps -1672 bps
-25.3% -8.6% -13.5% EPS (₹)
loss widened loss widened -12.58 -4.09 -4.81
Quality of profit
Pre-tax profit −₹43.7 Cr: core business −₹45.7 Cr, other income ₹2.0 Cr.
Core profit YoY: loss widened
Cash & debt
FY26 cash from operations −₹84.0 Cr.
Borrowings ₹270 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹197 ₹174
-11.7% below
AI read of the filing ZOTA Q1 Standalone Revenue Up 62.8% YoY to ₹127 Cr; Net Profit Declines to ₹1.90 Cr Neutral Standalone Revenue from Operations increased to ₹127.03 Cr from ₹78.01 Cr in Q1 FY26. Standalone Net Profit fell to ₹1.90 Cr compared to ₹5.90 Cr in the previous year's corresponding quarter. Invested ₹20.20 Cr in wholly-owned subsidiary Davaindia Health Mart Limited via a rights issue at ₹5,075 per share. Full analysis →
M Cap ₹189 Cr
P/E 13.7
PEG 0.62
Since results -53.2%
Profit +38% above its own trend Operating margin contracted 263 bps YoY 35% of pre-tax profit came from other income and one-off items FY26 operating cash flow was only 46% of profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+81.4% +22.2%
69.4 56.8 38.3 Operating profit
+16.8% -53.8%
3.3 7.2 2.8 OPM %
-263 bps -783 bps
4.8% 12.6% 7.4% Other income
+77.6% -59.3%
1.2 2.9 0.7 Net profit
+38.5% -57.0%
2.5 5.9 1.8 PAT margin %
-113 bps -669 bps
3.6% 10.3% 4.8% EPS (₹)
+36.4% -57.7%
0.30 0.71 0.22
Quality of profit
Pre-tax profit ₹3.3 Cr: core business ₹2.2 Cr, other income ₹1.2 Cr.
Core profit YoY: +22.2%
· reported profit +38.5%
Cash & debt
FY26 cash from operations ₹6.0 Cr:
46% of FY26 net profit of ₹13.1 Cr.
Borrowings ₹19.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹50.0 ₹69.4
+38.7% above Net profit ₹1.8 ₹2.5
+38.1% above
AI read of the filing 81% Revenue Growth in Q1 FY27; Medico Remedies Reports ₹69.40 Cr Revenue Positive Revenue from operations increased by 81.4% YoY to ₹69.40 cr from ₹38.25 cr in Q1 FY26. Net profit for the quarter rose 38.5% YoY to ₹2.52 cr compared to ₹1.82 cr in the same period last year. Domestic sales saw a massive sequential jump to ₹26.34 cr in Q1 FY27 from ₹2.74 cr in Q4 FY26. Full analysis →
M Cap ₹1,091 Cr
P/E 41.5
PEG —
Since results +2.8%
Turnaround: profit against a loss a year ago Operating margin contracted 518 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
-5.4% -0.5%
121 122 128 Operating profit
-31.5% +0.6%
16.5 16.4 24.1 OPM %
-518 bps +15 bps
13.6% 13.5% 18.8% Other income
-74.6% +377.6%
1.0 0.2 3.9 Net profit
from loss +6.5%
8.1 7.7 -101 PAT margin %
+8545 bps +44 bps
6.7% 6.3% -78.7% EPS (₹)
from loss -10.0%
0.18 0.20 -2.63
Quality of profit
Pre-tax profit ₹10.1 Cr: core business ₹9.1 Cr, other income ₹1.0 Cr.
Core profit YoY: -43.5%
Cash & debt
FY26 cash from operations ₹4.0 Cr.
Borrowings ₹139 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹118 ₹121
+3.0% in line
AI read of the filing Sigachi Q1 Net Profit at ₹8.14 Cr; ₹22.88 Cr Forfeited as 3.5 Cr Warrants Lapse Neutral Consolidated Net Profit of ₹8.14 Cr in Q1 FY27 vs a loss of ₹100.97 Cr in Q1 FY26. Forfeiture of ₹22.88 Cr representing the 25% upfront consideration for 3,50,57,990 lapsed warrants. Promoter-linked entities, including Amit Raj Sinha (HUF), were among those who allowed warrants to lapse. Full analysis →
M Cap ₹48,595 Cr
P/E 35.2
PEG 0.93
Since results +7.9%
Profit +43% above its own trend Operating margin expanded 598 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+20.8% +16.8%
2,788 2,388 2,309 Operating profit
+60.8% +38.3%
670 484 416 OPM %
+598 bps +375 bps
24.0% 20.3% 18.0% Other income
-22.7% -47.4%
25.3 48.0 32.7 Net profit
+82.2% +38.2%
424 307 233 PAT margin %
+513 bps +236 bps
15.2% 12.9% 10.1% EPS (₹)
+72.4% +34.4%
15.84 11.79 9.19
Quality of profit
Pre-tax profit ₹572 Cr: core business ₹547 Cr, other income ₹25.3 Cr.
Core profit YoY: +83.6%
· reported profit +82.2%
Cash & debt
FY26 cash from operations ₹1,142 Cr:
96% of FY26 net profit of ₹1,187 Cr.
Borrowings ₹809 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹2,483 ₹2,788
+12.3% above Net profit ₹297 ₹424
+42.7% above
AI read of the filing 72% YoY Consolidated PAT Growth in Q1 FY27; EBITDA Margins Expand to 22.88% Positive Consolidated Net Profit increased 72% YoY to 401.89 cr in Q1 FY27 Consolidated EBITDA margins expanded by 449 basis points to 22.88% from 18.39% YoY Export income grew 34% to 935.39 cr, driven by both formulations and APIs Full analysis →
M Cap ₹1,118 Cr
P/E 11.6
PEG 1.65
Since results -5.2%
Profit +19% above its own trend 51% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+15.1% -5.2%
177 187 154 Operating profit
+15.2% +9.7%
27.4 25.0 23.8 OPM %
+2 bps +210 bps
15.5% 13.4% 15.5% Other income
+58.9% from loss 24.3 -4.0 15.3 Net profit
+30.9% +202.0%
36.2 12.0 27.7 PAT margin %
+248 bps +1402 bps
20.4% 6.4% 18.0% EPS (₹)
+30.9% +211.4%
18.09 5.81 13.82
Quality of profit
Pre-tax profit ₹47.6 Cr: core business ₹23.3 Cr, other income ₹24.3 Cr.
Core profit YoY: +15.8%
· reported profit +30.9%
Cash & debt
FY26 cash from operations ₹106 Cr:
120% of FY26 net profit of ₹88.3 Cr.
Borrowings ₹4.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹166 ₹177
+6.6% above Net profit ₹30.5 ₹36.2
+18.7% above
AI read of the filing 31% YoY PAT Growth in Q1 FY27; Revenue Rises 15% to ₹177.3 Cr Positive Net Profit increased by 30.9% YoY to ₹36.23 Cr from ₹27.68 Cr in Q1 FY26 Revenue from operations grew 15.1% YoY to ₹177.28 Cr Earnings Per Share (EPS) for the quarter rose to ₹18.09 from ₹13.82 YoY Full analysis →
M Cap ₹6,975 Cr
P/E 49.1
PEG 2.13
Since results +36.9%
Profit -26% below its own trend Operating margin expanded 683 bps YoY Core business grew faster than reported profit (core profit +138%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+37.6% +11.1%
286 257 207 Operating profit
+84.9% +73.6%
76.4 44.0 41.3 OPM %
+683 bps +963 bps
26.8% 17.1% 19.9% Other income
-72.9% -12.7%
9.6 11.0 35.5 Net profit
+15.8% +38.8%
51.4 37.0 44.4 PAT margin %
-339 bps +359 bps
18.0% 14.4% 21.4% EPS (₹)
+15.9% +40.8%
4.73 3.36 4.08
Quality of profit
Pre-tax profit ₹75.5 Cr: core business ₹65.9 Cr, other income ₹9.6 Cr.
Core profit YoY: +138.2%
· reported profit +15.8%
Cash & debt
FY26 cash from operations ₹139 Cr:
103% of FY26 net profit of ₹135 Cr.
Borrowings ₹22.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹233 ₹286
+22.4% above Net profit ₹69.2 ₹51.4
-25.8% below
AI read of the filing Bliss GVS Q1 PAT Rises 16% YoY to ₹51.4 Cr; Revenue Surges 38% to ₹285.6 Cr Positive Consolidated Revenue from Operations grew 37.6% YoY to ₹285.58 Cr from ₹207.47 Cr in Q1 FY26 Consolidated Net Profit reached ₹51.37 Cr, a 38.9% increase over the ₹36.99 Cr reported in Q4 FY26 Basic EPS for the quarter improved to ₹4.73 compared to ₹4.08 in the year-ago period Full analysis →
M Cap ₹148 Cr
P/E 20.4
PEG 0.58
Since results +8.0%
Profit +630% above its own trend 39% of pre-tax profit came from other income and one-off items
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+34.5% +5.4%
88.6 84.1 65.9 Operating profit
+31.2% -24.9%
7.9 10.6 6.1 OPM %
-23 bps -361 bps
9.0% 12.6% 9.2% Other income
-39.3% from loss 0.4 -0.2 0.7 Net profit
+445.7% -68.4%
1.1 3.6 0.2 PAT margin %
+97 bps -300 bps
1.3% 4.3% 0.3% EPS (₹)
+446.2% -68.4%
0.71 2.25 0.13
Quality of profit
Pre-tax profit ₹1.1 Cr: core business ₹0.7 Cr, other income ₹0.4 Cr.
Core profit YoY: from loss
· reported profit +445.7%
Cash & debt
FY26 cash from operations ₹30.0 Cr:
475% of FY26 net profit of ₹6.3 Cr.
Borrowings ₹160 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹66.9 ₹88.6
+32.5% above Net profit ₹0.2 ₹1.1
+629.7% above
AI read of the filing Bal Pharma Q1 Profit Jumps 443% to ₹1.14 Cr; Approves ₹9 Cr Philippines JV & ₹8.4 Cr Warrants Positive Revenue from operations grew 34.5% YoY to ₹88.62 Cr in Q1 FY27 compared to ₹65.87 Cr in Q1 FY26. Net profit increased to ₹1.14 Cr from ₹0.21 Cr in the same quarter last year, a 443% jump. Approved a ₹9 Cr investment (approx. 8.6% of net worth) for a 65% stake in a new Philippines-based JV for pharmaceutical distribution. Full analysis →
M Cap ₹1,807 Cr
P/E 31.9
PEG 0.97
Since results -15.0%
Operating margin expanded 620 bps YoY 30% of pre-tax profit came from other income and one-off items Core business grew faster than reported profit (core profit +211%)
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+33.6% -6.6%
139 149 104 Operating profit
+112.2% +10.9%
23.3 21.0 11.0 OPM %
+620 bps +264 bps
16.7% 14.1% 10.5% Other income
+16.9% +271.4%
7.4 2.0 6.4 Net profit
+99.1% +41.5%
18.4 13.0 9.2 PAT margin %
+435 bps +450 bps
13.2% 8.7% 8.9% EPS (₹)
+99.1% +36.4%
29.78 21.84 14.96
Quality of profit
Pre-tax profit ₹24.5 Cr: core business ₹17.0 Cr, other income ₹7.4 Cr.
Core profit YoY: +210.8%
· reported profit +99.1%
Cash & debt
FY26 cash from operations ₹43.0 Cr:
90% of FY26 net profit of ₹47.6 Cr.
Borrowings ₹108 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹142 ₹139
-1.7% in line Net profit ₹18.5 ₹18.4
-0.5% in line
AI read of the filing NGL Fine-Chem Q1 FY27 Net Profit Jumps 99% YoY to ₹18.40 Cr; EPS at ₹29.78 Positive Consolidated Net Profit increased by 99.1% YoY to ₹18.40 Cr from ₹9.24 Cr. Consolidated Earnings Per Share (EPS) rose to ₹29.78 from ₹14.96 in June 2025. Profit Before Tax (Consolidated) grew to ₹24.48 Cr, a 106.7% increase over the ₹11.84 Cr reported in the same period last year. Full analysis →
M Cap ₹167 Cr
P/E —
PEG —
Since results -1.9%
Operating margin expanded 159 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+7.8% -16.7%
48.7 58.5 45.2 Operating profit
+250.8% -15.8%
1.1 1.3 0.3 OPM %
+159 bps +2 bps
2.3% 2.3% 0.7% Other income
+556.0% +209.4%
2.4 0.8 0.4 Net profit
loss widened loss widened -5.7 -5.0 -5.6 PAT margin %
+55 bps -327 bps
-11.8% -8.5% -12.3% EPS (₹)
loss widened loss widened -5.55 -3.32 -5.40
Quality of profit
Pre-tax profit −₹5.8 Cr: core business −₹8.2 Cr, other income ₹2.4 Cr.
Core profit YoY: loss widened
Against its own trend ?
Trend Actual Gap
Sales ₹51.2 ₹48.7
-4.8% in line
AI read of the filing ₹10 Cr Promoter Fundraise Approved Amidst ₹5.74 Cr Q1 Net Loss Watch Consolidated revenue for Q1 FY27 stood at ₹48.71 Cr, up from ₹45.20 Cr in Q1 FY26. API segment reported a loss of ₹8.04 Cr, significantly impacting the consolidated bottom line. Promoter Sunil L Mundra to infuse ₹10 Cr via 1.25 lakh equity shares and 5 lakh warrants at ₹160/unit. Full analysis →
M Cap ₹18,705 Cr
P/E 27.6
PEG 1.38
Since results -7.8%
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+19.6% +1.7%
610 600 510 Operating profit
+20.1% +4.6%
213 204 178 OPM %
+14 bps +98 bps
35.0% 34.0% 34.8% Other income
+44.8% +19.8%
33.5 28.0 23.2 Net profit
+18.8% +3.5%
179 173 151 PAT margin %
-21 bps +51 bps
29.3% 28.8% 29.5% EPS (₹)
+15.8% +4.0%
23.27 22.38 20.10
Quality of profit
Pre-tax profit ₹225 Cr: core business ₹192 Cr, other income ₹33.5 Cr.
Core profit YoY: +18.8%
· reported profit +18.8%
Cash & debt
FY26 cash from operations ₹523 Cr:
80% of FY26 net profit of ₹650 Cr.
Borrowings ₹5.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹566 ₹610
+7.9% above Net profit ₹181 ₹179
-1.0% in line
AI read of the filing Caplin Point Q1 PAT Rises 16% YoY to ₹177 Cr; Recommends ₹4 Final Dividend Positive Consolidated revenue from operations grew 19.6% YoY to ₹610.36 cr from ₹510.22 cr in Q1 FY26 Net profit attributable to owners rose 15.8% YoY to ₹176.91 cr compared to ₹152.80 cr in the previous year Recommended a final dividend of ₹4 per share (200%), totaling ₹8 for FY26 including the interim dividend Full analysis →
M Cap ₹14,007 Cr
P/E 26.9
PEG 1.68
Since results +12.2%
Profit +162% above its own trend Operating margin expanded 921 bps YoY
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+35.6% -1.8%
841 856 620 Operating profit
+113.0% +9.2%
213 195 100 OPM %
+921 bps +256 bps
25.3% 22.8% 16.1% Other income
+323.4% -27.4%
25.4 35.0 6.0 Net profit
+174.8% +7.0%
159 149 58.0 PAT margin %
+960 bps +155 bps
19.0% 17.4% 9.4% EPS (₹)
+169.0% +6.1%
3.47 3.27 1.29
Quality of profit
Pre-tax profit ₹207 Cr: core business ₹181 Cr, other income ₹25.4 Cr.
Core profit YoY: +155.2%
· reported profit +174.8%
Cash & debt
FY26 cash from operations ₹458 Cr:
109% of FY26 net profit of ₹420 Cr.
Borrowings ₹343 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹691 ₹841
+21.8% above Net profit ₹60.8 ₹159
+162.0% above
AI read of the filing 174% PAT growth: Marksans Pharma Q1 profit hits ₹159.4 Cr; expands in Europe via acquisitions Positive Consolidated PAT increased 173.9% YoY to ₹159.41 Cr from ₹58.20 Cr in Q1 FY26 Acquired 100% of QliniQ B.V. (Netherlands) for EUR 7.50 Million (approx. ₹70 Cr) effective April 1, 2026 Acquired ABCnow GmbH (Germany) for EUR 1.10 Million (approx. ₹10 Cr) to gain frontend sales capabilities Full analysis →
M Cap ₹687 Cr
P/E 12.2
PEG 0.11
Since results -23.9%
Profit -88% below its own trend Operating margin contracted 517 bps YoY FY26 operating cash flow was only 48% of profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+1.5% +0.4%
166 165 163 Operating profit
-33.6% -45.9%
16.2 30.0 24.4 OPM %
-517 bps -838 bps
9.8% 18.2% 15.0% Other income
+3.6% from loss 0.4 -3.0 0.3 Net profit
-76.0% -85.3%
3.2 22.0 13.5 PAT margin %
-631 bps -1137 bps
2.0% 13.3% 8.3% EPS (₹)
-77.4% -85.0%
0.93 6.21 4.12
Quality of profit
Pre-tax profit ₹4.6 Cr: core business ₹4.2 Cr, other income ₹0.4 Cr.
Core profit YoY: -68.1%
· reported profit -76.0%
Cash & debt
FY26 cash from operations ₹32.0 Cr:
48% of FY26 net profit of ₹66.5 Cr.
Borrowings ₹224 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹180 ₹166
-8.0% below Net profit ₹27.0 ₹3.2
-88.0% below
AI read of the filing 27,530 ESOP Shares Allotted; Mohan Kumar Rayana Re-appointed as Whole-time Director for 5 Years Neutral Allotment of 27,530 equity shares of Rs 10 face value following ESOP exercise Paid-up share capital increased to Rs 34.97 Cr from Rs 34.94 Cr Re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a 5-year term Full analysis →
M Cap ₹2,188 Cr
P/E 1.3
PEG 0.02
Since results +62.6%
Profit -10% below its own trend Operating margin expanded 736 bps YoY FY26 operating cash flow was only 3% of profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+7.4% -7.0%
126 135 117 Operating profit
+65.8% +19.1%
26.2 22.0 15.8 OPM %
+736 bps +458 bps
20.9% 16.3% 13.5% Other income
+29.7% -47.8%
7.8 15.0 6.0 Net profit
+57.7% -0.6%
24.8 25.0 15.8 PAT margin %
+632 bps +128 bps
19.8% 18.5% 13.5% EPS (₹)
+23.8% -3.7%
0.26 0.27 0.21
Quality of profit
Pre-tax profit ₹32.3 Cr: core business ₹24.4 Cr, other income ₹7.8 Cr.
Core profit YoY: +71.8%
· reported profit +57.7%
Cash & debt
FY26 cash from operations ₹58.0 Cr:
3% of FY26 net profit of ₹1,720 Cr.
Borrowings ₹1.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹132 ₹126
-4.7% in line Net profit ₹27.7 ₹24.8
-10.4% below
AI read of the filing Syncom Formulations Q1 Net Profit Jumps 56% YoY to ₹24.59 Cr Positive Net Profit increased by 56.3% YoY to ₹24.59 Cr from ₹15.73 Cr in Q1 FY26. Revenue from operations grew 7% YoY to ₹124.66 Cr compared to ₹116.55 Cr in the previous year. PBT margin expanded significantly to 24.1% in Q1 FY27 from 16.5% in Q1 FY26. Full analysis →
M Cap ₹6,352 Cr
P/E 12.8
PEG 0.46
Since results +7.3%
Profit +25% above its own trend FY26 operating cash flow was only 24% of profit
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+33.9% -89.5%
471 4,478 352 Operating profit
+40.3% -88.8%
73.1 651 52.1 OPM %
+71 bps +99 bps
15.5% 14.5% 14.8% Other income
-55.2% -87.2%
2.0 15.6 4.5 Net profit
+42.3% -88.4%
44.1 381 31.0 PAT margin %
+55 bps +87 bps
9.4% 8.5% 8.8% EPS (₹)
+42.3% +15.9%
7.71 6.65 5.42
Quality of profit
Pre-tax profit ₹59.0 Cr: core business ₹57.0 Cr, other income ₹2.0 Cr.
Core profit YoY: +49.2%
· reported profit +42.3%
Cash & debt
FY26 cash from operations ₹117 Cr:
24% of FY26 net profit of ₹484 Cr.
Borrowings ₹344 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹460 ₹471
+2.3% in line Net profit ₹35.4 ₹44.1
+24.6% above
AI read of the filing Innova Captab Q1 Standalone PAT Jumps 58% to ₹32.06 Cr; FY26 Financials to be Revised Watch Standalone Revenue from operations increased 39.5% YoY to ₹400.48 Cr from ₹286.98 Cr. Standalone Profit After Tax (PAT) surged 58% YoY to ₹32.06 Cr compared to ₹20.30 Cr in Q1 FY26. Profit Before Tax (PBT) stood at ₹43.03 Cr, a 57.7% increase over the ₹27.29 Cr reported in the year-ago period. Full analysis →
M Cap ₹1,471 Cr
P/E —
PEG —
Since results -5.4%
Profit -47% below its own trend Operating margin contracted 245 bps YoY 29% of pre-tax profit came from other income and one-off items Exceptional items of ₹-2.0 Cr in the quarter
₹ Cr YoY QoQ
Jun 2026 Mar 2026 Jun 2025
Sales
+9.5% -31.4%
103 150 94.0 Operating profit
-22.0% -76.0%
6.2 26.0 8.0 OPM %
-245 bps -1127 bps
6.1% 17.3% 8.5% Other income
-4.6% from loss 3.8 -3.0 4.0 Net profit
-45.4% -72.7%
4.4 16.0 8.0 PAT margin %
-427 bps -643 bps
4.2% 10.7% 8.5% EPS (₹)
-47.4% -73.0%
1.51 5.60 2.87
Quality of profit
Pre-tax profit ₹6.1 Cr: core business ₹4.3 Cr, other income ₹3.8 Cr, exceptional & other items −₹2.0 Cr.
Core profit YoY: -28.6%
· reported profit -45.4%
Cash & debt
FY26 cash from operations ₹36.0 Cr:
63% of FY26 net profit of ₹57.4 Cr.
Borrowings ₹2.0 Cr at Mar 2026.
Against its own trend ?
Trend Actual Gap
Sales ₹105 ₹103
-1.8% in line Net profit ₹8.3 ₹4.4
-47.1% below
AI read of the filing Amrutanjan Q1 PAT Rises 46% to ₹4.37 Cr; Women's Hygiene Segment Grows 27% YoY Positive Revenue from operations increased 9.5% YoY to ₹102.97 Cr from ₹94.05 Cr. Net Profit (PAT) grew 46.6% YoY to ₹4.37 Cr despite a ₹2.03 Cr exceptional item. Women's Hygiene segment revenue rose to ₹36.36 Cr, now contributing ~35% of total revenue. Full analysis →
Standouts so far
Among companies with a market cap of ₹1,000 Cr or more, so a tiny base does not top the list. Price reaction: last close against the close before the filing.
Reporting in the next three days
HCL Technologies (Mon 12 Oct), ICICI Prudential (Mon 12 Oct), RBL Bank (Mon 12 Oct), Swan Defence (Mon 12 Oct), Gujarat State (Mon 12 Oct), Swaraj Engines (Mon 12 Oct), Plastiblends India (Mon 12 Oct), UMIYA BUILDCON (Mon 12 Oct), Alkali Metals (Mon 12 Oct), Gradiente Infotainment (Mon 12 Oct), Agri-Tech (India) (Mon 12 Oct), Abhishek Integrations (Mon 12 Oct), Rudra Ecovation (Mon 12 Oct), Newtrac Foods (Mon 12 Oct), Inani Securities (Mon 12 Oct), Neil Industries (Mon 12 Oct), Adroit Industries (Mon 12 Oct), TYPHOON (Mon 12 Oct), UNIVARTS (Mon 12 Oct), VERONICAPRO (Mon 12 Oct), ICICI Prudential (Tue 13 Oct), Tata Elxsi (Tue 13 Oct), Transformers And Rectifiers (Tue 13 Oct), Anand Rathi (Tue 13 Oct) and 87 more.
Full results calendar →
How to read this page
The numbers. Each card is one company's Q1 FY27 results as filed with NSE or BSE, read from the
filing within hours of its release, in ₹ crore. We show the consolidated statement, or the standalone one when
the consolidated figures are a copy of it or have no year-ago quarter to compare with. YoY compares with the same
quarter a year earlier and QoQ with the quarter before (the previous half-year for companies that report every six months).
A swing between profit and loss is described in words: a percentage across it would mislead.
Margins. Operating margin (OPM) is operating profit, before depreciation, interest and other income,
as a share of sales; PAT margin is net profit as a share of sales. Their changes are in basis points
(100 bps = 1 percentage point).
Quality of profit. Core profit is operating profit minus interest and depreciation: what the business
itself earned before tax. The rest of pre-tax profit is other income (interest on cash, dividends, gains on
investments) and exceptional or one-off items. We flag a quarter when that share is 25% or more,
and when reported profit grew much faster than core profit. For banks we compare pre-provision profit with net
profit, since a fall in provisions can lift profit without the business growing.
Against its own trend. We do not have analyst consensus estimates, and we do not make them up. Instead
each company is measured against the path it was on: the same quarter last year, grown at the median of its
last four year-on-year growth rates (held between −50% and +100%; at least two growth rates needed). Sales
5% or more above that, or net profit 10% or more above, is "above trend";
as far below is "below trend". It answers "was this quarter better or worse than the company's own recent
run?", which consensus does not.
Cash and debt. Profit is an accounting figure; cash is harder to dress up. For each company we show
its operating cash flow for the last financial year as a share of that year's net profit (flagged under
50%, or when it is negative despite a profit), and its borrowings at the latest balance sheet
against the one six months earlier (flagged at a 25% move). Balance sheets come with the
September and March results, cash-flow statements with the March results.
Price since results. The latest close against the last close before the filing (a filing after 3:30 pm
counts from the next session). It is a fact about the market's reaction, not advice.
Market cap groups. Large cap is the 100 largest companies by market value and mid cap the next 150
(SEBI's ranking); below that, small cap is ₹5,000 Cr or more, micro cap ₹500 Cr or more, nano cap below.
Data source Quarterly results filed by listed companies with NSE and BSE (Regulation 33 of SEBI LODR), read from each filing; share prices from the exchanges; market cap and P/E from our daily fundamentals snapshot.
Last updated 12 Oct 2026, 12:14 IST
